drugset
drugset / Trial / NCT04346407

Dronabinol for Post-operative Pain After Lumbar Fusion

NCT04346407 ↗

Phase 4 Unknown 90 enrolled Jeffrey L Gum MD
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Impact of 2.5mg of oral Dronabinol daily versus placebo on post-operative opioid consumption on patients aged 18 to 65 years old undergoing 1 to 3 level posterolateral fusion

Timeline

Start
2020-09-01
Primary completion
2023-09-01
Completion
2023-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronabinol Other / unclassified 2.5 mg Oral

Indications

No indication recorded.